McAdam LLC’s 10x Genomics TXG Stock Holding History

McAdam LLC’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$396K	Buy	+4,378	New	+$256K	0.01%	330

Other funds holding TXG

Counterpoint Mutual Funds San Diego, California $1.16B AUM 33.78% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Financial Consulate Hunt Valley, Maryland $899M AUM 14.82% 1-Year Est. Return

MIC

Maxi Investments CY Limassol, Cyprus $545M AUM 21.2% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return

Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

McAdam LLC's TXG Position: Q3 2026 in Review

McAdam LLC opened a new position in 10x Genomics (TXG) in Q3 2026: 4,378 shares worth $396K. The stake represents 0.01% of the portfolio and ranks #330 among its holdings.

96 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

McAdam LLC held 4,378 shares of 10x Genomics worth $396K as of Q3 2026.
10x Genomics was a new McAdam LLC position in Q3 2026.
10x Genomics made up 0.01% of McAdam LLC's portfolio in Q3 2026, its #330 holding.
96 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on McAdam LLC's 13F filing for Q3 2026, filed 21 Oct 2026.